Almirall's Nine-month 2023 Results: : vimarsana.com

BARCELONA, Spain, November 09, 2023--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.

Related Keywords

Austria , Spain , United States , Germany , United Kingdom , Hong Kong , Berlin , Barcelona , Comunidad Autonoma De Cataluna , Taiwan , Netherlands , Denmark , Italy , Macau , Switzerland , China , Spanish , Chinese , Omar Ram , Epimab Biotherapeutics , Astra Zeneca Covis , Eli Lilly , European Union , Corporate Communications , European Academy Of Dermatology , European Medicines Agency , Venereology Congress , Simcere Pharmaceutical Group , Spanish Stock Exchange , Committee For Medicinal Products Human Use , European Commission , Simcere Pharmaceutical Group For , Healthcare Products Regulatory Agency , Chinese National Medical Products Administration , European Association Of Dermatology , Net Sales , European Dermatology , New Drug Application , Astra Zeneca , Net Debt , Gallardo Piqu , European Association , Medicinal Products , Human Use , European Academy , Global Assessment , Eczema Area , Severity Index , Annual Fall Clinical Dermatology Conference , Large Field , Ichnos Science , Greater China , Mainland China , Fabs In Tandem Immunoglobulin , Noble Purpose , Safe Treatment , Psoriatic Disease , Real World Prospective Cohort Study , Patient Reported Outcomes , Tirbanibulin Effectiveness , Cutaneous Medicine , Lebrikizumab Is Maintained , Two Years , Clinical Dermatology , Almirall , Psoriasis , Plaque Psoriasis , Lebrikizumab , M , Uropean Academy Of Dermatology And Venereology ,